Friday 16 October 2026
Export ALXO’s income statement to Excel — free account
ALX Oncology Holdings Inc.
ALXO Healthcare Biotechnology
In the quarter to June 2026, EPS grew 73.5%, free cash flow grew 31.7% and total debt fell 3.34%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.06
0.06
+6.00%
Follow ALXO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
2.19 | 1.82 | 6.95 | 9.36 | |
Current Ratio |
2.40 | 2.07 | 7.21 | 9.71 | |
Net Debt/EBITDA |
2.24 | 1.52 | 6.96 | 7.05 | |
Debt/Assets |
12.22% | 16.51% | 4.77% | 6.03% | |
Debt/Equity |
0.23 | 0.38 | 0.06 | 0.07 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.77 | 0.83 | 1.04 | 0.89 | |
Capex/Depreciation |
(9.33) | (1.32) | (2.63) | (0.14) | |
Interest Coverage |
(55.23) | (60.11) | (57.30) | (63.27) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.32) | (0.35) | (0.18) | (0.12) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.32) | (0.35) | (0.18) | (0.12) | |
Cash per Share |
1.13 | 0.83 | 1.34 | 1.02 | |
Shareholders Equity per Share |
0.84 | 0.48 | 1.45 | 1.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.84 | 0.48 | 1.45 | 1.00 | |
Free Cash Flow |
(17.15) | (19.03) | (18.70) | (16.03) | |
Working Capital |
38.79 | 26.17 | 125.39 | 128.68 | |
Capital Expenditures |
(0.06) | (0.05) | (0.05) | 0.03 | |
Net Current Asset Value |
28.59 | 17.66 | 118.58 | 118.82 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
7.24 | 4.71 | 3.90 | 3.96 | |
Average Assets |
134.22 | 103.41 | 149.61 | 128.07 | |
Average Common Equity |
90.80 | 69.80 | 119.82 | 100.30 |
Columns are period end dates